株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ハウスダストダニアレルギー : パイプライン分析

House Dust Mite Allergy - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 246018
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.10円で換算しております。
Back to Top
ハウスダストダニアレルギー : パイプライン分析 House Dust Mite Allergy - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 49 Pages
概要

ハウスダストダニアレルギーとは一般にハウスダストの中に生息する小さな虫に対する アレルギー反応であり、くしゃみや鼻水、鼻詰まり、鼻のかゆみ、目の痛みなどの症状があります。喘息や湿疹などの引き金になる可能性もあり、巻き上げられたハウスダストに近づくと悪化する場合があります。家族歴や年齢などが素因となり、治療法には抗ヒスタミン剤、充血緩和剤、コルチコステロイドの利用などがあります。

当レポートでは、世界におけるハウスダストダニアレルギー治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

ハウスダストダニアレルギーの概要

治療薬の開発

  • ハウスダストダニアレルギー向けパイプライン製品:概要
  • ハウスダストダニアレルギー向けパイプライン製品:比較分析

ハウスダストダニアレルギー:開発中の治療薬:企業別

ハウスダストダニアレルギー:開発中の治療薬:大学・研究機関別

ハウスダストダニアレルギー:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ハウスダストダニアレルギー:開発中の製品:企業別

ハウスダストダニアレルギー:開発中の製品:大学・研究機関別

ハウスダストダニアレルギー:治療薬開発に従事している企業

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Stallergenes S.A.

ハウスダストダニアレルギー:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AllerDM
  • Allergen for House Dust Mite Allergy
  • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis
  • BM-35
  • MK-8237
  • PL-103
  • STG-320
  • Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8983IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2017, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 2 and 1 respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • House Dust Mite Allergy - Overview
  • House Dust Mite Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • House Dust Mite Allergy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • House Dust Mite Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergy Therapeutics Plc
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • HAL Allergy BV
    • Stallergenes Greer plc
  • House Dust Mite Allergy - Drug Profiles
    • Acarovac Quattro - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AllerDM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-35 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • House Dust Mite Allergy - Dormant Projects
  • House Dust Mite Allergy - Discontinued Products
  • House Dust Mite Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval
      • Jan 27, 2017: Stallergenes Greer Announces Positive Top-Line Results Of Phase 3 Study For Pediatric House Dust Mite-Induced Allergic Rhinitis
      • Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX
      • Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA
      • Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
      • Apr 05, 2016: Stallergenes Greer Announces The Approval Of Actair In Australia
      • Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France
      • Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark
      • Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan
      • Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan
      • Jun 09, 2015: ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
      • Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet
      • Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet
      • Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study
      • Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for House Dust Mite Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H1 2017
  • House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H1 2017
  • House Dust Mite Allergy - Pipeline by Anergis SA, H1 2017
  • House Dust Mite Allergy - Pipeline by Biomay AG, H1 2017
  • House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2017
  • House Dust Mite Allergy - Pipeline by HAL Allergy BV, H1 2017
  • House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H1 2017
  • House Dust Mite Allergy - Dormant Projects, H1 2017
  • House Dust Mite Allergy - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for House Dust Mite Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top